UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 413

Sortiert nach

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

PloS one, 2017-08, Vol.12 (8), p.e0182665-e0182665

2017

Link zum Volltext

Verfügbarkeit prüfen

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

Diagnostic pathology, 2016-10, Vol.11 (1), p.95-95, Article 95

2016

Link zum Volltext

Verfügbarkeit prüfen

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation

Journal for Immunotherapy of Cancer, 2016-11, Vol.4 (1), p.76-76, Article 76

2016

Link zum Volltext

Verfügbarkeit prüfen

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

Liver cancer (Basel ), 2021-06, Vol.10 (3), p.249-259

2021

Link zum Volltext

Verfügbarkeit prüfen

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2019-03, Vol.380 (12), p.1103-1115

2019

Link zum Volltext

Verfügbarkeit prüfen

HLA-A03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study

The lancet oncology, 2022-01, Vol.23 (1), p.172-184

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort

European journal of cancer (1990), 2019-03, Vol.109, p.154-161

2019

Link zum Volltext

Verfügbarkeit prüfen

Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma

Cancer discovery, 2024-03, Vol.14 (3), p.406

2024

Link zum Volltext

Verfügbarkeit prüfen

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

Clinical cancer research, 2022-02, Vol.28 (4), p.738-747

2022

Link zum Volltext

Verfügbarkeit prüfen

Hallmarks of Resistance to Immune-Checkpoint Inhibitors

Cancer immunology research, 2022-04, Vol.10 (4), p.372-383

2022

Link zum Volltext

Verfügbarkeit prüfen

Consistent, Persistent Expression from Modified Retroviral Vectors in Murine Hematopoietic Stem Cells

Proceedings of the National Academy of Sciences - PNAS, 1998-08, Vol.95 (17), p.10182-10187

1998

Link zum Volltext

Verfügbarkeit prüfen

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations

Journal for Immunotherapy of Cancer, 2016-11, Vol.4 (1), p.77-77, Article 77

2016

Link zum Volltext

Verfügbarkeit prüfen

In vivo Restoration of Laminin 5 β3 Expression and Function in Junctional Epidermolysis Bullosa

Proceedings of the National Academy of Sciences - PNAS, 2001-04, Vol.98 (9), p.5193-5198

2001

Link zum Volltext

Verfügbarkeit prüfen

Use of TMB and PD-L1 to predict outcomes of checkpoint inhibitor treatment

Journal of clinical oncology, 2019-03, Vol.37 (8_suppl), p.150-150

2019

Link zum Volltext

Verfügbarkeit prüfen

Sustainable systemic delivery via a single injection of lentivirus into human skin tissue

Human gene therapy, 2001-08, Vol.12 (12), p.1551-1558

2001

Link zum Volltext

Verfügbarkeit prüfen

HLA-A03 and response to immune checkpoint blockade in cancer: an epidemiological study

The lancet oncology, 2021-12, Vol.23 (1), p.172-184

2021

Link zum Volltext

Verfügbarkeit prüfen

Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4547-4547

2021

Link zum Volltext

Verfügbarkeit prüfen

DELTA-1: A global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9594-TPS9594

2022

Link zum Volltext

Verfügbarkeit prüfen

First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4072-4072

2019

Link zum Volltext

Verfügbarkeit prüfen

Molecular characteristics of renal cell carcinoma (RCC) risk groups from JAVELIN Renal 101

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.744-744

2020

Link zum Volltext

Verfügbarkeit prüfen

Tremelimumab, a fully human anti-CTLA-4 monoclonal antibody, optimal dosing regimen for patients with unresectable malignant mesothelioma (MM)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3042-3042

2015

Link zum Volltext

Verfügbarkeit prüfen

Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.101-101

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of laminin 5 β3 gene versus protein replacement on gene expression patterns in junctional epidermolysis bullosa

Human gene therapy, 2001-07, Vol.12 (11), p.1443-1448

2001

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 413

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(383)
Mit Volltextzugriff
(357)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(410)
Japanisch
(67)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(282)
Life Sciences & Biomedicine
(239)
Humans
(184)
Female
(102)
Animals
(101)
Male
(101)
Biological And Medical Sciences
(85)
Medical Sciences
(58)
Adult
(52)
Mice
(49)
Middle Aged
(46)
Immunology
(45)
Aged
(34)
Fundamental And Applied Biological Sciences. Psychology
(34)
Oncology
(31)
Medicine, Research & Experimental
(30)
Research & Experimental Medicine
(30)
Physical Sciences
(27)
Biochemistry & Molecular Biology
(26)
Infectious Diseases
(24)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

HLA-A03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study

Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort

Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

Hallmarks of Resistance to Immune-Checkpoint Inhibitors

Consistent, Persistent Expression from Modified Retroviral Vectors in Murine Hematopoietic Stem Cells

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations

In vivo Restoration of Laminin 5 β3 Expression and Function in Junctional Epidermolysis Bullosa

Use of TMB and PD-L1 to predict outcomes of checkpoint inhibitor treatment

Sustainable systemic delivery via a single injection of lentivirus into human skin tissue

HLA-A03 and response to immune checkpoint blockade in cancer: an epidemiological study

Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

DELTA-1: A global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma

First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100)

Molecular characteristics of renal cell carcinoma (RCC) risk groups from JAVELIN Renal 101

Tremelimumab, a fully human anti-CTLA-4 monoclonal antibody, optimal dosing regimen for patients with unresectable malignant mesothelioma (MM)

Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

Impact of laminin 5 β3 gene versus protein replacement on gene expression patterns in junctional epidermolysis bullosa

Suchergebnisse filtern